Core Insights - China National Pharmaceutical Group (Sinopharm) has renewed its distribution partnership with Fuhong Hanlin, which will last from January 1, 2026, to December 31, 2028, focusing on the commercialization of innovative biopharmaceutical products [1][10]. Group 1: Partnership with Fuhong Hanlin - Fuhong Hanlin, a biopharmaceutical company, has a strong product matrix and approximately 50 molecules in development, ensuring a stable supply of new products for Sinopharm [3][5]. - The sales cap for the renewed partnership is set at 12.224 billion RMB over three years, with expected sales growth driven by new product launches and existing product demand [5][17]. - Specific sales growth expectations include a 0.8% increase in 2027 and a 14.2% increase in 2028, attributed to new indications and innovative products [5][17]. Group 2: Strategic Collaborations - Sinopharm is accelerating collaborations with upstream industrial partners, including a recent strategic partnership with Pierre Fabre, a French pharmaceutical company [5][19]. - The company is also engaging with other multinational pharmaceutical giants like AstraZeneca and Bristol-Myers Squibb to explore strategic synergies and innovative business models [19][20]. - Domestic collaborations are also progressing, with Sinopharm partnering with Tianjin Pharmaceutical Group to enhance channel integration and product offerings [21][22]. Group 3: Retail and Operational Performance - Sinopharm's retail arm, Guoda Pharmacy, is transforming its procurement system and has seen a 11.3% year-on-year sales growth in core products from industrial partners in the first half of 2025 [23]. - The company reported a revenue of 431.5 billion RMB in the first three quarters of 2025, with a reduced year-on-year decline of 2.47% [23]. - Recent leadership changes, including the resignation of Chairman Zhao Bingxiang, signal a potential shift in strategic direction for Sinopharm [24].

截至月份: 2025年11月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 國藥控股股份有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01099 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,341,810,740 | RMB | | 1 RMB | | 1,341,810,740 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 1,341,810,740 | RMB | | 1 RMB | | 1,341,810,740 | | 2. 股份分類 | 普通股 | 股份類別 | ...

SINOPHARM GROUP CO. LTD. * 01099 為本人╱吾等的代理人出席將於2025年12月19日（星期五）上午九時半於中華人民共和國（「中 國」）上海市黃浦區龍華東路385號國藥控股大廈1401會議室舉行的本公司股東特別大會（「股東 特別大會」）或其任何續會，並於該會或其任何續會上代表本人╱吾等，依照下列指示就股東特 別大會通告所載決議案投票。如無作出指示，則由本人╱吾等的代理人酌情決定投票。 | | 普通決議案 贊成 | （附註5） | 反對 | （附註5） | | --- | --- | --- | --- | --- | | 1. | 審議及酌情批准委任晉斌先生為第六屆董事會非執行董 | | | | | | 事，並授權董事會釐定其酬金及授權本公司董事長或任何 | | | | | | 一位執行董事與其簽訂服務合約或該等其他文件或補充協 | | | | | | 議或契據。 | | | | | 2. | 審議及酌情批准委任楊秉華先生為第六屆董事會執行董 | | | | | | 事，並授權董事會釐定其酬金及授權本公司董事長或任何 | | | | | | 一位執行董事與其簽訂服務合約或該等其他 ...

股東特別大會通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SINOPHARM GROUP CO. LTD. * 01099 茲通告國藥控股股份有限公司（「本公司」）謹訂於2025年12月19日（星期五）上午九時半假 座中華人民共和國（「中國」）上海市黃浦區龍華東路385號國藥控股大廈1401會議室舉行股 東特別大會（「股東特別大會」），藉以考慮並酌情通過以下決議案： 普通決議案 * 本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港 公司。 - 1 - 1. 審議及酌情批准委任晉斌先生為第六屆董事會非執行董事，並授權董事會釐定其酬 金及授權本公司董事長或任何一位執行董事與其簽訂服務合約或該等其他文件或補 充協議或契據。 2. 審議及酌情批准委任楊秉華先生為第六屆董事會執行董事，並授權董事會釐定其酬 金及授權本公司董事長或任何一位執行董事與其簽訂服務合約或該等其他文件或補 充協議或契據。 ...

此乃要件 請即處理 閣下對本通函如有任何疑問，應徵詢獨立專業意見。 閣下如已出售或轉讓名下所有國藥控股股份有限公司H股，應立即將本通函連同隨附的代理人 委任表格送交買方或承讓人或經手買賣或轉讓之銀行、股票經紀或其他代理商，以便轉交買方 或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SINOPHARM GROUP CO. LTD. * 01099 (1)建議委任非執行董事； (2)建議委任執行董事；及 (3)股東特別大會通告 董事會函件載於本通函第3-8頁。本公司謹訂於2025年12月19日（星期五）上午九時半假座中國 上海市黃浦區龍華東路385號國藥控股大廈1401會議室舉行股東特別大會，召開股東特別大會 的通告將連同本通函按股東就收取公司通訊已作出選擇的方式寄發予股東。 如股東擬委任代理人出席股東特別大會，務請按照適用代理人委任表格印列之指示填妥及交回 代理人委任表格。本代理人委任表格必須由 閣下或 閣下以書面正式授權的人士簽署，如屬 ...

Core Points - Zhao Bingxiang has resigned from his position as Chairman of Sinopharm Holdings after 14 months due to work arrangement reasons [2][3] - Jin Bin, a veteran from the Sinopharm system, will succeed Zhao as Chairman, with Li Ying also proposed as a non-executive director [3] - Sinopharm Holdings is a subsidiary of China National Pharmaceutical Group and a leading player in China's pharmaceutical distribution industry [3] Financial Performance - In the first half of 2024, Sinopharm Holdings reported total revenue of 294.73 billion yuan, a year-on-year decrease of 2.07% [4] - The medical device distribution and retail businesses experienced revenue declines of 7.08% and 6.43%, respectively, while the pharmaceutical distribution business saw a slight revenue increase of 0.47% [4] - The company's net profit attributable to shareholders fell by 9.76% to 3.704 billion yuan due to declining revenue and lower gross margins [4] Strategic Initiatives - Zhao emphasized the importance of innovation and service transformation in the company's annual report, aiming to enhance profitability and value [4] - The company is focusing on strengthening its service-oriented business models, including marketing services, third-party logistics, and private label manufacturing [4] - In the first half of 2025, the company continued to face revenue and profit declines, with a reported revenue of 286 billion yuan, down 2.95% year-on-year [5]

Policy Developments - The National Healthcare Security Administration exposed a healthcare fraud industry chain in Shanghai, leading to the prosecution of an individual for fraud, resulting in significant losses to the national healthcare fund [1] - The crackdown on healthcare fraud has become more systematic and normalized in recent years, highlighting the importance of protecting the healthcare fund [1] Drug and Device Approvals - Anglicon received a drug registration certificate for Ertugliflozin Metformin Extended-Release Tablets, aimed at improving blood sugar control in adults with type 2 diabetes [2] - Betta Pharmaceuticals announced that its application for the marketing authorization of Ensartinib Capsules for treating ALK-positive non-small cell lung cancer has been accepted by the European Medicines Agency [3] - Innovent Biologics received approval for its IL-23p19 monoclonal antibody for the treatment of moderate to severe plaque psoriasis in adults [4] - Warner Pharmaceuticals obtained a drug registration certificate for Formoterol Fumarate Inhalation Solution, intended for the maintenance treatment of COPD [5] - Shanghai Pharmaceuticals announced that its Tramadol Hydrochloride Injection passed the consistency evaluation for generic drugs, which may enhance its market competitiveness [6] Major Industry Events - Biontech received a milestone payment of $250 million from Bristol-Myers Squibb related to the Iza-bren project, with potential for additional payments based on future milestones [7] - Jining Pharmaceutical plans to invest 893 million yuan in a hospital expansion project to meet the growing health demands in the region [8] - Maiwei Biotech completed Phase IIa clinical trials for its innovative drug 9MW1911 in COPD patients, showing significant reductions in acute exacerbation rates [9] Shareholder Actions - Sanofi Biotech announced plans for shareholders to reduce their holdings by a total of 0.0240% of shares due to personal financial needs [10] Management Changes - Sinopharm Holdings announced management changes, including the resignation of several executives and the appointment of new leadership, which will take effect upon shareholder approval [11]

Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the resignation of key board members and the appointment of new directors, indicating a significant leadership change within the company [1] Group 1: Resignations - Mr. Zhao Bingxiang has resigned from multiple positions including non-executive director, chairman of the board, and various committee roles effective from the date of appointment of his successors at the shareholders' meeting [1] - Ms. Feng Rongli has also resigned from her roles as non-executive director and committee member, with her resignation effective upon the appointment of her successor [1] Group 2: Appointments - The board has proposed the appointment of Mr. Jin Bin and Ms. Li Ying as non-executive directors [1] - Mr. Jin has been elected as chairman and authorized representative, pending shareholder approval for his non-executive director appointment [1] - Mr. Jin will also serve as the chairman of the nomination committee, strategic and investment committee, and as a member of the legal compliance and environmental, social, and governance committee, subject to shareholder approval [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the resignation of key board members and the appointment of new directors, indicating a significant leadership change within the company [1] Group 1: Resignations - Mr. Zhao Bingxiang has resigned from multiple positions including non-executive director, chairman of the board, and various committee roles effective from November 28, 2025 [1] - Ms. Feng Rongli has also resigned from her roles as non-executive director and committee member effective from the same date [1] Group 2: Appointments - The board has proposed the appointment of Mr. Jin Bin and Ms. Li Ying as non-executive directors [1] - Mr. Jin Bin is set to be elected as chairman and authorized representative of the board, pending shareholder approval at the upcoming general meeting [1] - Mr. Jin will also take on roles as chairman of the nomination committee, strategic and investment committee, and member of the legal compliance and environmental, social, and governance committee, subject to shareholder approval [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 公告 （1） 建議更换非執行董事、董事長及授權代表； （2） 董事委員會組成變更；及 （3） 暫停辦理股份過戶登記 （1）建議更換非執行董事、董事長及授權代表 非執行董事、董事長及授權代表辭任 國藥控股股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，由 於工作安排原因，於 2025 年 11 月 28 日，趙炳祥先生（「趙先生」）已向董事會提出辭任 非執行董事、董事會董事長（「董事長」）、董事會提名委員會（「提名委員會」）主席、 董事會戰略與投資委員會（「戰略與投資委員會」）主席、董事會法律合規與環境、社會 及治理委員會（「法律合規與環境、社會及治理委員會」）委員及本公司授權代表（根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第 3.05 條規定）（「授權代表」） 職務；馮蓉麗女士（「馮女士」）已向董事會提出辭任非執行董事、董事會薪酬委員會委 員及提名委員會委員職務，上述辭 ...